SCHEMBL20475487

SCHEMBL20475487

CC(C)(C)OC(=O)N1CCN(c2ccc(O)cn2)CC1=O

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ME2 P23368 10/20 0.44
▸ ME1 P48163 10/20 0.44
▸ ME3 Q16798 10/20 0.44
▸ GPR119 Q8TDV5 4/20 0.43
▸ DDB1 Q16531 1/20 0.42
▸ CRBN Q96SW2 1/20 0.42
▸ CKS1B P61024 1/20 0.39
▸ SKP1 P63208 1/20 0.39
▸ SKP2 Q13309 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ MAP4K4 O95819 1/20 0.38
▸ RET P07949 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29521781 1.00 ME2 (0.44) ME2ME1ME3GPR119DDB1
SCHEMBL29522264 0.87 AKR1C3 (0.44) GPR119DDB1CRBNCKS1BSKP1
SCHEMBL15206161 0.87 AKR1C3 (0.44) GPR119DDB1CRBNCKS1BSKP1
SCHEMBL29890806 0.81 GPR119 (0.60) ME2ME1ME3GPR119DDB1
SCHEMBL13279435 0.81 GPR119 (0.60) ME2ME1ME3GPR119DDB1
SCHEMBL20475492 0.81 ME2 (0.49) ME2ME1ME3ESR2
SCHEMBL20475502 0.80 USP30 (0.49) GPR119DDB1CRBNCKS1BSKP1
SCHEMBL20956331 0.77 TRPV1 (0.42) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL15908706 0.75 GPR119 (0.53) GPR119CKS1BSKP1SKP2HDAC1
SCHEMBL20475504 0.74 GPR119 (0.41) GPR119DDB1CRBNCKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114369095-B Aminopyrimidine compounds useful as SSAO inhibitors and methods for preparing the same 伊莱利利公司 2025-03-14 — — CN disclosed
CN-114369095-A Aminopyrimidine compounds useful as SSAO inhibitors and methods of making the same 伊莱利利公司 2022-04-19 — — CN disclosed
CN-108778278-B Aminopyrimidine compounds useful as SSAO inhibitors 伊莱利利公司 2022-01-28 — — CN disclosed
EP-3582780-B1 AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS LILLY CO ELI (US) 2021-10-13 — — EP disclosed
US-10471060-B2 Amino pyrimidine compounds useful as SSAO inhibitors ELI LILLY AND COMPANY (US) 2019-11-12 — — US disclosed
US-20190275041-A1 AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS ELI LILLY AND COMPANY (US) 2019-09-12 — — US disclosed
US-10278970-B2 Amino pyrimidine compounds useful as SSAO inhibitors ELI LILLY AND COMPANY (US) 2019-05-07 — — US disclosed
US-20180296560-A1 AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS ELI LILLY AND COMPANY 2018-10-18 — — US disclosed
WO-2018151985-A1 AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS ELI LILLY AND COMPANY (US) 2018-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10278970-B2 Amino pyrimidine compounds useful as SSAO inhibitors DPYD, TYMP, NUDT1 ME2 1907/4885ME1 2147/4885ME3 1683/4885
US-20180296560-A1 AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS DPYD, TYMP, NUDT1 ME2 1907/4885ME1 2147/4885ME3 1683/4885
US-10471060-B2 Amino pyrimidine compounds useful as SSAO inhibitors DPYD, TYMP, NUDT1 ME2 1907/4885ME1 2147/4885ME3 1683/4885
US-20190275041-A1 AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS DPYD, TYMP, NUDT1 ME2 1907/4885ME1 2147/4885ME3 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback